**Table S3.** General characteristic of the treatment protocols used in all studies included in the systematic review.

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Author** | **Combination chemotherapy** | **Dose** | **Frequency** | **Route** |
| Kar et al., 1993 | *Trans*-aconitic acid (TAA) +  Sodium stibogluconate (SSG) or  Pentamidine (PET) or Allopurinol (ALL) | TAA (200 or 400 mg/kg);  SSG (50 mg of Sbv/kg);  PET (8 mg/kg); ALL (15 mg/kg) | daily | p.o. (TAA, ALL); ip. (SSG, PET) |
| Oliva, 1998 | Paromomycin (PAR) +  Meglumine antimoniate (MEG) | PAR (3.5 mg/kg);  MEG (20 Sb/kg) | daily (PAR);  bis in d. (MEG) | sc/im |
| Carter et al., 2003 | Buthionine sulfoximine (BSO) + Sodium stibogluconate (SSG) | BSO (34 mg/kg);  SSG (70 or 282 mg of Sbv/kg) | Once | iv/iv |
| Haldar et al., 2009 | Diperoxovanadate (DPV6) + Sodium antimony gluconato (SAG) | PV6 (0.5 µmol/30g bw)  SSG (50 mg/kg) | alt. d. (DPV6)  bis in 7d. (SSG) | ip/im |
| Mutiso et al., 2011 | Diminazene (DIM) + Artesunate (ART) | DIM (12.5 mg/kg); ART (12.5 mg/kg) | daily | ? |
| Shakya et al., 2012a | PAM3Cys + Miltefosine (MTF) | PAM3Cys (100 µg/animal)  MTF (2.5, 5, 20 mg/kg) | once (PAM3Cys)  daily (MTF) | ip/p.o. |
| Shakya et al., 2012b | Tufisin (TUF) + Miltefosine (MTF) | TUF (60 μg/animal)  MTF (2.5, 5, 20 mg/kg) | once (TUF)  daily (MTF) | ip/p.o. |
| Bhattacharjee et al., 2014 | Glycyrrhizic acid (GA) +  Sodium antimony gluconato (SAG) | GA (5, 10, 25, 50, 75 mg/kg)  SAG (250 mg/kg) | alt. d. | ip/im |
| Corral et al., 2014 | Allicin (ALI) +  Amphotericin B (AMB) | ALI (5 mg/kg)  AMB (1, 5 mg/kg) | daily | ip/ip |
| **SSG**: Sodium Stibogluconate; **ATO**: Atovaquone; **PAR**: Paromomycin; **MEG**: Meglumine Antimoniate; **EFC**: Enrofloxacin; **KET**: Ketoconazole**; MET**: Metronidazole; **DIM**: Diminazene; **ART**: Artesunate; **MTF**: Miltefosine; **LPV**: Lopinavir. **SbV**: pentavalent antimony; **ip**: intraperitoneal; **p.o.**: per oral route; **sc**: subcutaneous; **im**: intramuscular. **alt. d.**: every alternate day; **bis in 7d**: twice in week; **bis in d.**: twice in day | | | | |

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Author** | **Combination chemotherapy** | **Dose** | **Frequency** | **Route** |
| Mwololo et al., 2015 | Diminazene (DIM) +  Chloroquine (CHQ) | DIM (12. mg/kg)  CHQ (12. mg/kg) | daily | ip/ip |
| Kahdem et al., 2016 | CAL-101 (CAL) +  Amphotericin B (AMB) | CAL (0.05 mg/animal)  AMB (0.1 mg/kg) | daily | ip/ip |
| Hendrickx et al., 2017 | Paromomycin (PAR) + Miltefosine (MTF) | MTF (10 or 20 mg/Kg);  PAR (180 or 350 mg/Kg) | daily | p.o./ip. |
| Joice et al., 2017 | DB766 + Posaconazole (POS) or  Ketoconazole (KET) | POS and KET (7.5, 15, 30 mg/kg);  DB766 (19, 38, 75 mg/kg) | daily | p.o. |
| Rebello, 2019 | Miltefosine (MTF) + Lopinavir (LPV) | MTF (1.92; 3.85; 7.7 mg/Kg);  LPV (246.6; 493.2 mg/Kg) | bis in 7d | p.o. |

**Table S3 (C*ontinuation*).** General characteristic of the treatment protocols used in all studies included in the systematic review.

**SSG**: Sodium Stibogluconate; **ATO**: Atovaquone; **PAR**: Paromomycin; **MEG**: Meglumine Antimoniate; **EFC**: Enrofloxacin; **KET**: Ketoconazole**; MET**: Metronidazole; **DIM**: Diminazene; **ART**: Artesunate; **MTF**: Miltefosine; **LPV**: Lopinavir. **SbV**: pentavalent antimony; **ip**: intraperitoneal; **p.o.**: per oral route; **sc**: subcutaneous; **im**: intramuscular. **alt. d.**: every alternate day; **bis in 7d**: twice in week; **bis in d.**: twice in day.